

Association between increased serum IL-23 levels and ACPA positivity in patients with rheumatoid arthritis

H. Kohno, T. Sugimoto, Y. Yoshida, S. Mokuda, S. Hirata, E. Sugiyama

Supplementary Table S1. Baseline demographical and clinical characteristics of the patients included in the study.

Characteristics	ACPA -, n=31	ACPA +, n=44	<i>p</i> -value
Female	17 (55%)	36 (82%)	0.0195*
Age, yrs	72.0 (63.5-77.0)	60.5 (48.0-73.3)	0.0016
dVAS, mm	50.0 (30.0-62.0)	35.5 (25.0-57.0)	0.1905
pVAS, mm	56.0 (38.5-72.5)	48.0 (30.0-61.3)	0.1722
gVAS, mm	52.0 (31.5-72.0)	50.0 (37.8-60.5)	0.6237
Tender joint counts, n	3.0 (2.0-7.0)	2.0 (1.0-4.0)	0.0745
Swollen joint counts, n	5.0 (3.0-10.0)	3.5 (1.8-7.0)	0.0996
DAS28-CRP	4.6 (3.8-5.2)	3.6 (2.8-4.3)	0.0039
DAS28-ESR	5.2 (4.6-5.8)	4.4 (3.6-5.4)	0.0129
SDAI	23.5 (17.6-30.4)	16.5 (11.4-24.1)	0.0243
CDAI	22.0 (16.3-25.4)	15.0 (10.1-21.6)	0.0267
CRP, mg/dl	1.5 (0.5-3.1)	0.4 (0.1-1.7)	0.1888
ESR, mm/h	51.0 (35.0-74.5)	32.5 (17.0-60.3)	0.0771
RF titre, IU/ml	6.3 (6-34.8)	94.3 (53.4-147.1)	<0.0001
RF-positive	13 (42%)	43 (98%)	<0.0001
Anti-CCP titre, U/ml	1.3 (0.6-1.3)	450.3 (324.1-500.0)	-

Data presented as n (%) or median (IQR). Statistical analysis; t-test, * Fisher's exact test. CCP: cyclic citrullinated peptide; CDAI: Clinical Disease Activity Index; DAS: Disease Activity Score; dVAS: doctor's visual analogue scale; gVAS: general visual analogue scale; pVAS: pain visual analogue scale; RF: rheumatoid factor; SDAI: Simplified Disease Activity Index.